The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

The FDA has approved Eisai (ESALF) and Biogen's (BIIB) supplemental application for four-week maintenance dosing of their Alzheimer's drug Lequembi. Read more here.

Additionally, the FDA accepted Eisai’s Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for ...

The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of ...

Additionally, the FDA accepted Eisai’s Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date ...